StockInvest_us
Posted - 1 day ago
Signal alert: $CERE - Double Top https://stockinvest.us/l/HcjLzslxXL
fda_tracker
Posted - 2 days ago
$CERE Phase 2 trial w/est May completion date NCT04244175: https://www.clinicaltrials.gov/study/NCT04244175 Trial Tracker: https://www.fdatracker.com/trial-tracker/
NakadasuTellaria
Posted - 04/25/24
$RCI Barclays Trims Rogers Communications (NYSE:RCI) Target Price to $46.00 $CERE Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Receives $41.40 Average Target Price from Analysts $SPGI S&P Global Inc. (NYSE:SPGI) Receives $464.22 Average Target Price from Analysts $DCGO BTIG Research Trims DocGo (NASDAQ:DCGO) Target Price to $11.00 $WIMI Evaluate Research reiterated a "buy" rating with $7 latest price target for WIMI Hologram Cloud(NASDAQ: WIMI)
the_FDA
Posted - 04/18/24
$CERE Great. Now filing as soon as possible so patients can get access to it as soon as possible.
luiselen
Posted - 04/18/24
$SNOW Brokerages Set Snowflake Inc. (NYSE:SNOW) Target Price at $202.50 $RCI Barclays Trims Rogers Communications (NYSE:RCI) Target Price to $46.00 $CERE Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Receives $41.40 Average Target Price from Analysts $WIMI Evaluate Research reiterated a "buy" rating with $7 latest price target for WIMI Hologram Cloud(NASDAQ: WIMI)
ForestFoxes
Posted - 04/18/24
I am even more excited about Annovis’ $ANVS P3 Early-Stage Parkinson’s disease study then their P2/3 Alzheimer’s study based on the size (523 n) and duration (7-8 months) with expected results this month. I’m super happy for those affected by Parkinson’s with Cerevel Therapeutics’ P3 study (507 n & 6.76 months) results today! https://investors.cerevel.com/news-releases/news-release-details/cerevel-therapeutics-announces-positive-topline-results-0 Amazing timing with AbbVie $ABBV being in the process of acquiring $CERE for $8.7B (which includes ALL of their pipeline) with the transaction expected to close by mid-2024. What a DEAL for ABBV 🙌 Hopefully, Annovis will also be acquired sometime this year 🤞 This is really great news for Parkinson’s patients with multiple companies (approx. 120+) working towards Rx's but with limited success until now 😊👍 P.S. Anavex $AVXL has a pending Alzheimer’s submission to the EMA and a Parkinson’s peer-review article pending.
OpenOutcrier
Posted - 04/18/24
$CERE (+1.3% pre) $ABBV AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug - SA https://ooc.bz/l/30702
DonCorleone77
Posted - 04/18/24
$CERE Cerevel Therapeutics' tavapadon meets Phase 3 primary endpoint in Parkinson's Cerevel Therapeutics announced positive topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon, the first and only D1/D5 receptor partial agonist being studied as a once-daily treatment for Parkinson's disease. The TEMPO-3 trial evaluated the efficacy, safety and tolerability of tavapadon as an adjunctive therapy to levodopa in adults. The trial met its primary endpoint - patients treated with tavapadon adjunctive to LD experienced a clinically meaningful and statistically significant increase of 1.1 hours in total "on" time without troublesome dyskinesia compared to those treated with LD and placebo. A statistically significant reduction in "off" time, the key secondary endpoint, was also observed for the tavapadon treatment arm. Tavapadon was generally well tolerated. The safety profile observed in the TEMPO-3 trial was consistent with prior clinical trials of tavapadon. The majority of adverse events reported were mild to moderate in severity. Full results from the TEMPO-3 study will be submitted for presentation at future medical meetings and used to support regulatory submissions of tavapadon as a treatment for Parkinson's disease. Topline results from the Phase 3 monotherapy trials for tavapadon, TEMPO-1 and TEMPO-2, are expected in the second half of 2024.
G101SPM
Posted - 04/18/24
$CERE $41.90 ask.... BUY/ADD NEW LONG POSITION with SPM 87.63 tag to 54.00 EXIT in midterm. CAUSE FOR SPM TAG IMPROVEMENT: Cerevel Therapeutics announces positive topline results for tavapadon in Phase 3 Adjunctive trial for people living with Parkinson’s Disease (41.60) Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total "on" time without troublesome dyskinesia compared with placebo over 27 weeks; Results demonstrate tavapadon's potential to provide the right balance of motor control, safety and tolerability for people living with Parkinson's disease.
Stock_Titan
Posted - 04/18/24
$CERE Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
https://www.stocktitan.net/news/CERE/cerevel-therapeutics-announces-positive-topline-results-for-yv63gswgxnv7.html
precise
Posted - 04/16/24
$CERE Anyone buyout arbitraging it?
Doorkey
Posted - 03/31/24
$CERE $RVMD Low risk adds.
fda_tracker
Posted - 2 months ago
$CERE Phase 3 trial w/est Mar completion date NCT04542499: https://www.clinicaltrials.gov/study/NCT04542499 Trial Tracker: https://www.fdatracker.com/trial-tracker/
Treesnow
Posted - 2 months ago
$CERE short til 37
paiocje
Posted - 2 months ago
$CERE what is the expected closing date? The merger announcement states "middle of 2024". Does that imply that Aug'24 calls will be safe? How are options traders playing this?
MMCT
Posted - 02/27/24
$VKTX From the antitrust and m&a perspective i do not think it will be acuired by $LLY or $NVS any time soon or ever.
They are the biggest competitors and usually antitrust would block or ask for a second request like $CERE .
Before the data was released i expected $LLY would offer 50$ while it was at 36$. Now with the data release everything changed
The other big pharma will not take the risk to buy it with an additional premium of 50-100% for the best in class P2 data. They need to pay at least 50%-100% more but there are not many who have that much cash.
BUT i think they can sell it on their own or even have a good partnership and compete on the market. If it sucessful we will see next $NVO and our next 3 digit billion mc by 2030. All depend on the P3 and commercialization.
I am bullish and longterm. 🫰
ChelseaMurphy289
Posted - 02/21/24
$CERE is on the rise, but COEP's anticipated surge based on analyst estimates suggests a compelling growth story.
CTFNLighthouse
Posted - 02/20/24
$CERE $ABBV AbbVie’s proposed acquisition of Ceravel Therapeutics was approved by shareholders on Friday. Further, the parties each received a second request from the FTC in connection with the agency’s review of the deal. The parties continue to expect to close the deal in the middle of the year.
maikelm82
Posted - 02/12/24
$IMGN acquisition completed by $ABBV next up is $CERE to be finalized for $45
insiderbuyingselling
Posted - 3 months ago
$CERE new insider selling: 2161 shares. http://insiderbuyingselling.com/?t=CERE
insiderbuyingselling
Posted - 3 months ago
$CERE new insider selling: 2506 shares. http://insiderbuyingselling.com/?t=CERE
Quantumup
Posted - 3 months ago
UBS🏁 $AXSM Buy/$111~is bullish on Auvelity's launch/ $AXSM' pipeline opps w/ upcoming late-stage clinical readouts. UBS est $2.4B rev '29. Auvelity could become a leading brand in depression, generating $1B by '30. +VE P3 AD/narcolepsy data should drive stock OP. $krtx $bmy $cere $abbv
Investocracy
Posted - 3 months ago
Surging 700% in just a few DAYS, this is the story of three insane trades that banked MILLIONS of dollars. $IMGN $ABBV $CERE $EYPT https://pennystocks.today/rampant-insider-trading-of-biotech-stocks/
Quantumup
Posted - 01/25/24
Goldman Sachs⬆️ $NBIX $153 was $134/Buy comm opp4 crinecerfont has become more visible following success of Ph3 studies in CAH; looks4 cont'd Ingrezza OP 4Q23 rev-GS/Cons $510M/$504M&FY24-GS/Cons $2.13B/$2.11B); muscarinic space deals $ABBV $CERE- $BMY $KRTX provide proof2deep pipe.
shortvolumes
Posted - 01/24/24
2024-01-23 Short sale volume (not short interest) for $CERE is 37%. http://shortvolumes.com/?t=CERE via @shortvolumes
